肠-肺轴菌群与结核病研究进展

doi:10.12183/j.scjpm.2023.1005

摘要/Abstract

摘要： 人体内存在丰富的菌群,对维持人体正常生理功能十分重要。根据肠道与肺部的联系及影响,人们提出了肠-肺轴的概念。目前多项研究提示,在结核病的不同病程以及抗结核治疗前后,肠道菌群及肺部菌群发生了一定的比例失调。它们不仅可以单独作用,两者间还会相互作用而影响疾病的发生、发展。但是肠-肺轴菌群与结核病之间互相影响的机制以及如何通过肠-肺轴菌群治疗结核病尚不明确。因此,本文将从肠-肺轴菌群的概述、联系、肠-肺轴菌群与结核病的相关研究以及针对菌群失调的宿主进行菌群定向治疗的有关研究结果进行综述。

关键词: 结核病, 肺部菌群, 肠道菌群, 宿主菌群定向治疗

中图分类号:

R521

陈茜, 张国良, 何太平. 肠-肺轴菌群与结核病研究进展[J]. 华南预防医学, 2023, 49(8): 1005-1009.

参考文献

[1] 宋敏, 陆普选, 方伟军, 等. 2022年WHO全球结核病报告:全球与中国关键数据分析[J]. 新发传染病电子杂志, 2023,8(1):87-92.
[2] Eribo OA, du Plessis N, Ozturk M, et al. The gut microbiome in tuberculosis susceptibility and treatment response: Guilty or not guilty?[J] Cell Mol Life Sci, 2020,77(8):1497-1509.
[3] Desai M, Oppenheimer J.Elucidating asthma phenotypes and endotypes: Progress towards personalized medicine[J]. Ann Allergy Asthma Immunol, 2016,116(5):394-401.
[4] Almeida A, Mitchell AL, Boland M, et al.A new genomic blueprint of the human gut microbiota[J]. Nature, 2019,568(7753):499-504.
[5] Marsland BJ, Trompette A, Gollwitzer ES.The gut-lung axis in respiratory disease[J]. Ann Am Thorac Soc, 2015(Suppl 2):S150-156.
[6] Thornton CS, Mellett M, Jarand J, et al.The respiratory microbiome and nontuberculous mycobacteria: An emerging concern in human health[J]. Eur Respir Rev, 2021,30(160):200299.
[7] Barcik W, Boutin RCT, Sokolowska M, et al.The role of lung and lut microbiota in the pathology of asthma[J]. Immunity, 2020,52(2):241-255.
[8] Segal LN, Alekseyenko AV, Clemente JC, et al.Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation[J].Microbiome, 2013,1(1):19.
[9] Iwase T, Uehara Y, Shinji H, et al.Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization[J]. Nature, 2010,465(7296):346-349.
[10] Enaud R, Prevel R, Ciarlo E, et al.The gut-lung axis in health and respiratory diseases: A place for inter-organ and inter-kingdom crosstalks[J]. Front Cell Infect Microbiol, 2020,10:9.
[11] Marsland BJ, Gollwitzer ES.Host-microorganism interactions in lung diseases[J]. Nat Rev Immunol, 2014,14(12):827-35.
[12] Sze MA, Tsuruta M, Yang SW, et al.Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs[J]. PLoS One, 2014,9(10):e111228.
[13] Namasivayam S, Sher A, Glickman MS, et al.The microbiome and tuberculosis: Early evidence for cross talk[J]. mBio, 2018,9(5).
[14] Verheijden K, Van Bergenhenegouwen J, Garssen J, et al.Treatment with specific prebiotics or probiotics prevents the development of lung emphysema in a mouse model of COPD[J]. Eur J Pharmacol, 2011(668):e12-e13.
[15] Zhuang H, Cheng L, Wang Y, et al.Dysbiosis of the gut microbiome in lung cancer[J]. Front Cell Infect Microbiol, 2019,9:112.
[16] Soret P, Vandenborght LE, Francis F, et al.Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis[J]. Sci Rep, 2020,10(1):3589.
[17] Brown RL, Sequeira RP, Clarke TB.The microbiota protects against respiratory infection via GM-CSF signaling[J]. Nat Commun, 2017,8(1):1512.
[18] Budden KF, Gellatly SL, Wood DL, et al.Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017,15(1):55-63.
[19] He Y, Wen Q, Yao F, et al.Gut-lung axis: The microbial contributions and clinical implications[J]. Crit Rev Microbiol, 2017,43(1):81-95.
[20] Perrone EE, Jung E, Breed E, et al.Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis[J]. Shock, 2012,38(1):68-75.
[21] Coopersmith CM, Stromberg PE, Davis CG, et al.Sepsis from pseudomonas aeruginosa pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest[J]. Crit Care Med, 2003: 31, 1630-1637.
[22] 司秀影, 李勇军, 史梦迪, 等. 基于“肺-肠”轴探讨肠道微生态与支气管哮喘的关系[J]. 中华中医药学刊, 2022,40(9):163-166.
[23] Hu Y, Feng Y, Wu J, et al.The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients[J]. Front Cell Infect Microbiol, 2019,9:90.
[24] Parikh A, Vinnard C, Fahrenfeld N, et al.Revisiting John Snow to meet the challenge of nontuberculous mycobacterial lung disease[J]. Int J Environ Res Public Health, 2019,16(21):4250.
[25] Winglee K, Eloe-Fadrosh E, Gupta S, et al. Aerosol mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota[J]. PLoS One, 2014,9(5):e97048.
[26] Arias L, Goig GA, Cardona P, et al.Influence of gut microbiota on progression to tuberculosis generated by high fat diet-induced obesity in C3HeB/FeJ mice[J]. Front Immunol, 2019,10:2464.
[27] Hu Y, Yang Q, Liu B, et al.Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs[J]. J Infect, 2019,78(4):317-322.
[28] Balcells ME, Yokobori N, Hong BY, et al.The lung microbiome, vitamin D, and the tuberculous granuloma: A balance triangle[J]. Microb Patho, 2019,131:158-163.
[29] 王侠, 陆军, 胡韵, 等. 辅助性T细胞分泌的细胞因子在结核病中的作用研究进展[J]. 中华医院感染学杂志, 2022,32(12):1911-1916.
[30] Amaral EP, Vinhaes CL, Oliveira-de-Souza D, et al. The interplay between systemic inflammation, oxidative stress, and tissue remodeling in tuberculosis[J]. Antioxid Redox Signal, 2021,34(6):471-485.
[31] Wu J, Liu W, He L, et al.Sputum microbiota associated with new, recurrent and treatment failure tuberculosis[J]. PLoS One, 2013,8(12):e83445.
[32] Zhang M, Shen L, Zhou X, et al.The microbiota of human lung of pulmonary tuberculosis and the alteration caused by anti-tuberculosis drugs[J]. Curr Microbiol, 2022,79(11):321.
[33] Huang SF, Yang YY, Chou KT, et al.Systemic proinflammation after Mycobacterium tuberculosis infection was correlated to the gut microbiome in HIV-uninfected humans[J]. Eur J Clin Invest, 2019,49(5):e13068.
[34] Wang Y, Deng Y, Liu N, et al.Alterations in the gut microbiome of individuals with tuberculosis of different disease states[J]. Front Cell Infect Microbiol, 2022,12:836987.
[35] Luo M, Liu Y, Wu P, et al.Alternation of gut microbiota in patients with pulmonary tuberculosis[J]. Front Physiol, 2017,8:822.
[36] 曹振辉, 刘永仕, 潘洪彬, 等. 乳酸菌的益生功能及作用机制研究进展[J]. 食品工业科技, 2015,36(24):366-370, 377.
[37] Manos J, Hu H, Rose BR, et al.Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.[J]. Eur J Clin Microbiol Infect Dis, 2013,32(12):1583-1592.
[38] Holm JP, Hilberg O, Noerskov-Lauritsen N, et al. Pseudomonas aeruginosa in patients without cystic fibrosis is strongly associated with chronic obstructive lung disease[J]. Dan Med J, 2013,60(6):A4636.
[39] Zakharkina T, Heinzel E, Koczulla RA, et al.Analysis of the airway microbiota of healthy individuals and patients with chronic obstructive pulmonary disease by T-RFLP and clone sequencing[J]. PLoS One, 2013,8(7):e68302.
[40] Comberiati P, Di Cicco M, Paravati F, et al.The role of gut and lung microbiota in susceptibility to tuberculosis[J]. Int J Environ Res Public Health, 2021,18(22):12220.
[41] Wipperman MF, Fitzgerald DW, Juste MAJ, et al.Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed[J]. Sci Rep, 2017,7(1):10767.
[42] Negi S, Pahari S, Bashir H, et al.Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice[J]. Eur J Immunol, 2020,50(12):1976-1987.
[43] Young C, Walzl G, Du Plessis N.Therapeutic host-directed strategies to improve outcome in tuberculosis[J]. Mucosal Immunol, 2020,13(2):190-204.
[44] Gibson GR, Roberfroid MB.Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics[J]. J Nutr, 1995,125(6):1401-1412.
[45] Gibson GR, Hutkins R, Sanders ME, et al.Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017,14(8):491-502.
[46] Swanson KS, Gibson GR, Hutkins R, et al.The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics[J]. Nat Rev Gastroenterol Hepatol, 2020,17(11):687-701.
[47] Protsyuk R, Omelchuk S, Galan I.Nutritional correction of protein metabolism as a method of secondary prevention in patients with pulmonary tuberculosis[J]. Mod Trends Sci Prac, 2021,1,52-60.
[48] Azad MAK, Sarker M, Li T, et al.Probiotic species in the modulation of gut microbiota: An overview[J]. Biomed Res Int, 2018,2018:1-8.
[49] Gavrilova NN,Ratnikova IA,Sadanov AK,et al.Application of probiotics in complex treatment of tuberculosis[J]. Int J Eng Res Appl, 2014(4):13-18.
[50] Bravo M, Combes T, Martinez FO, et al.Lactobacilli isolated from wild boar (sus scrofa) antagonize Mycobacterium bovis Bacille Calmette-Guerin (BCG) in a species-dependent manner[J]. Front Microbiol, 2019,10:1663.
[51] Budden KF, Shukla SD, Rehman SF, et al.Functional effects of the microbiota in chronic respiratory disease[J]. Lancet Respir Med, 2019,7(10):907-920.
[52] Negatu DA, Yamada Y, Xi Y, et al.Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in Mycobacterium tuberculosis[J]. mBio, 2019,10(2).
[53] Shah T, Shah Z, Baloch Z, et al.The role of microbiota in respiratory health and diseases,particularly in tuberculosis[J]. Biomed Pharmacother, 2021,143:112108.